The University of Southampton
University of Southampton Institutional Repository

Application for consent to release a GMO – organisms other than higher plants: Experimental challenge of the human nasopharynx with recombinant Neisseria lactamica expressing the meningococcal type V autotransporter protein, Neisseria Adhesin A (NadA).

Application for consent to release a GMO – organisms other than higher plants: Experimental challenge of the human nasopharynx with recombinant Neisseria lactamica expressing the meningococcal type V autotransporter protein, Neisseria Adhesin A (NadA).
Application for consent to release a GMO – organisms other than higher plants: Experimental challenge of the human nasopharynx with recombinant Neisseria lactamica expressing the meningococcal type V autotransporter protein, Neisseria Adhesin A (NadA).
The purpose of the genetic modification is to construct a strain of the exclusively human, nasopharyngeal commensal bacterium, Neisseria lactamica (Nlac) that expresses on its surface the outer membrane protein, Neisseria Adhesin A (NadA). NadA is an adhesin protein found in the close relative of Nlac, Neisseria meningitidis (Nmen), which is the causative agent of meningococcal disease. The genetically modified organism (GMO) will be used to investigate the role of NadA in the colonisation of the nasopharynx and associated immune responses in a controlled human bacterial challenge. The Experimental Human Challenge group, previously based at the University of Sheffield and now located at the University of Southampton, has conducted two previous human bacterial challenges in adult volunteers, using wild type Nlac strain, Y92-1009. The primary objective of the proposed study is to verify that nasopharyngeal challenge of humans with GM-Nlac is safe. Secondary objectives are determining the impact of NadA expression on the frequency of nasopharyngeal colonisation by GM-Nlac and the type(s) of immune responses generated locally and systemically to these bacteria. Ultimately this strategy may confer benefit as a bacterial medicine expressing genes with therapeutic or prophylactic potential within the human nasopharynx.
UK Department of the Environment
Laver, Jay
b2996398-2ccf-40f0-92b8-f338f3de796b
Read, Robert
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Laver, Jay
b2996398-2ccf-40f0-92b8-f338f3de796b
Read, Robert
b5caca7b-0063-438a-b703-7ecbb6fc2b51

Laver, Jay and Read, Robert (2017) Application for consent to release a GMO – organisms other than higher plants: Experimental challenge of the human nasopharynx with recombinant Neisseria lactamica expressing the meningococcal type V autotransporter protein, Neisseria Adhesin A (NadA).

Record type: Other

Abstract

The purpose of the genetic modification is to construct a strain of the exclusively human, nasopharyngeal commensal bacterium, Neisseria lactamica (Nlac) that expresses on its surface the outer membrane protein, Neisseria Adhesin A (NadA). NadA is an adhesin protein found in the close relative of Nlac, Neisseria meningitidis (Nmen), which is the causative agent of meningococcal disease. The genetically modified organism (GMO) will be used to investigate the role of NadA in the colonisation of the nasopharynx and associated immune responses in a controlled human bacterial challenge. The Experimental Human Challenge group, previously based at the University of Sheffield and now located at the University of Southampton, has conducted two previous human bacterial challenges in adult volunteers, using wild type Nlac strain, Y92-1009. The primary objective of the proposed study is to verify that nasopharyngeal challenge of humans with GM-Nlac is safe. Secondary objectives are determining the impact of NadA expression on the frequency of nasopharyngeal colonisation by GM-Nlac and the type(s) of immune responses generated locally and systemically to these bacteria. Ultimately this strategy may confer benefit as a bacterial medicine expressing genes with therapeutic or prophylactic potential within the human nasopharynx.

Text
170727 southampton-17r5001-parta1 - Version of Record
Download (1MB)
Text
170727 gmo-application-southampton-17R5001-parta2-6 - Version of Record
Download (206kB)
Text
171019 gmo-17r5001-acre-advice - Version of Record
Download (370kB)

More information

Published date: 27 July 2017

Identifiers

Local EPrints ID: 421329
URI: https://eprints.soton.ac.uk/id/eprint/421329
PURE UUID: 4a4223c2-7829-4f83-9c74-3513deb142cc
ORCID for Robert Read: ORCID iD orcid.org/0000-0002-4297-6728

Catalogue record

Date deposited: 01 Jun 2018 16:30
Last modified: 14 Mar 2019 01:36

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×